Friedhelm Blobel, Ph.D.
Friedhelm Blobel, Ph.D., has been our President, Chief Executive Officer and a Director since 2006. Before joining the Company, Dr. Blobel served most recently as President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a South San Francisco based biopharmaceutical company. Prior to joining Gryphon in July 2000, Dr. Blobel spent more than 20 years as an executive with the Hoechst Group and the Boehringer Mannheim Group, including many responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer, General Manager of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas) in Tokyo, Japan, Senior Vice President of Research & Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana. Dr. Blobel earned his doctorate degree (“Dr.rer.nat.”; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany. He serves as a Director of Pelikan Technologies, Inc., a Palo Alto based private Biotech company.
back to top

Gary Titus
Gary Titus has served as Chief Financial Officer of SciClone Pharmaceuticals, Inc. since 2008. Mr. Titus brings to SciClone his in-depth experience in working with public corporations in a variety of areas, including financial planning and analysis, SEC reporting, investor relations, business development, and corporate strategy. Mr. Titus served most recently as Senior Vice President of Finance and Chief Financial Officer at Kosan Biosciences, prior to its acquisition by Bristol-Myers Squibb, in which transaction he played a significant role. Prior to that, Mr. Titus was Chief Financial Officer and Vice President at Nuvelo, Inc. Earlier in his career, Mr. Titus held a variety of positions with increasing management responsibilities at other companies, including Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc., and Johnson & Johnson's healthcare division LifeScan, Inc. Mr. Titus earned a Bachelor of Science degree in Accounting from University of South Florida and a Bachelor of Science degree in Finance from University of Florida and is a Certified Public Accountant. He also completed the Global BioExecutive Program at UC Berkeley's Haas School of Business and is a member of several professional organizations..
back to top

Hans P. Schmid
Hans P. Schmid is the President and Managing Director of SciClone Pharmaceuticals International, Ltd. and has been with the Company since 2001. Mr. Schmid has 25 years of financial and pharmaceutical experience in the U.S. and international markets. Prior to joining SciClone, Mr. Schmid was Chief Financial Officer from December 1999 to April 2001 for Questcor Pharmaceuticals, Inc. and Senior Vice President, International Business Development from February 1997 to September 1999 for Oread, Inc., a contract pharmaceutical company. From 1985 to 1997 he worked at Syntex Corporation as Vice President of Finance and Administration for Pharmaceutical Operations Asia/Pacific region, at F. Hoffmann-LaRoche as Senior Vice President, Finance and Head of Administrative Services for Roche Bioscience. Previously he held financial and operational positions with Itel Corporation in Germany, Japan, England and the U.S. Mr. Schmid received his BA from the Commercial Trade School, Lucerne, Switzerland, and has studied International Business Management and Finance at San Francisco State University. A Swiss, Hans speaks German, French and conversational Japanese.
back to top

Israel Rios, M.D.
Israel Rios, M.D. has served as Chief Medical Officer since joining SciClone Pharmaceuticals, Inc. in October 2005. Dr. Rios has over 30 years of experience in the biotechnology and pharmaceutical industries. Dr. Rios is responsible for the design and oversight of all clinical trials, clinical operations, drug safety and the evaluation of new development candidates. He serves as an officer and senior vice president in the company and is a member of the Senior Management Team. From 2003 to 2005 he served as Vice President of Clinical Affairs for Dendreon Corporation and was responsible for all clinical and operational activities related to the development of late-stage immunotherapeutic candidates for androgen independent prostate cancer (AIPC) and advanced breast cancer. From 1993 to 2003, Dr. Rios was at Berlex Laboratories (the U.S. affiliate of Schering AG of Germany ) most recently as Vice President of Oncology Development, where he oversaw the development of Fludara, Campath and Betaseron. From 1984 to 1993, Dr. Rios was Senior Director of Anti-Infective Clinical Research at Marion Merrell Dow, Inc. where he directed the clincal development and helped manage the New Drug Application (NDA) submissions of several anti-infective products. From 1978 to 1984, Dr. Rios held several escalating positions at Bristol-Myers, most recently as Director of Clinical Research. Dr. Rios earned his M.D. degree at the Central University of Venezuela. He completed his internship and residency in internal medicine at Mount Sinai Hospital in Hartford , Connecticut , and his fellowship in infectious diseases at Hartford Hospital in Hartford , Connecticut .
back to top

Cynthia W. Tuthill, Ph.D.
Cynthia W. Tuthill, Ph.D ., Senior Vice President, Scientific Affairs, and Chief Scientific Officer, has over 20 years of experience in the biotechnology and pharmaceutical industries. Dr. Tuthill has been with SciClone since October of 1991, where she is responsible for design and oversight of all nonclinical studies, leads several clinical development projects, and oversees both project management and manufacturing. Prior to joining SciClone, Dr. Tuthill was a senior product development scientist at Becton Dickinson Immunocytometry Systems, responsible for development of manufacturing methods, according to Good Manufacturing Processes, for new reagents for the assessment of viral diseases. From 1984 to 1990, she was a senior scientist at California Biotechnology, Inc. (now Scios, Inc.). At California Biotechnology she was project manager for several large heart disease therapeutic projects, as well as being responsible for analysis and purification of recombinant human proteins. Dr. Tuthill earned her undergraduate degree, summa cum laude, from the University of California , Berkeley , and her Ph.D. in protein biochemistry with highest honors from Harvard University .
back to top


Jeffery Lange
Jeffery Lange has served as Vice President, Business Development since August 2008. Mr. Lange served most recently as Director, Business Development & Licensing Finance at Novartis in East Hanover , NJ where he was responsible for licensing, divestiture, co-marketing, and merger and acquisition valuation as part of a global negotiation team for Novartis Pharma General Medicines. Prior to that, Mr. Lange held various positions within Novartis including the Head of Strategic Financial Planning in Novartis' Pharma General Medicine group in Basel , Switzerland , and Manager of Business Development and Planning at Novartis Agribusiness. Earlier in his career, he held a variety of positions in planning and analysis, finance and accounting. Mr. Lange earned an M.B.A. with a specialization in Finance from the University of Chicago and a B.B.A. in Accounting from the University of Iowa .
back to top

Randy J. McBeath
Randy McBeath has served as Vice President, Marketing of SciClone Pharmaceuticals, Inc. since May 2000. Mr. McBeath has twenty years of experience in the biotech, pharmaceutical and chemical industry in international sales and marketing, general management, business development, research and development, and manufacturing. At SciClone, Mr. McBeath is responsible for the worldwide development of promotional and educational materials as well as training programs to support ZADAXIN marketing worldwide. Prior to joining SciClone, Mr. McBeath served as the Director of Marketing for Coulter Pharmaceuticals from 1997 to 1999. From 1989 to 1997, Mr. McBeath was the Global Director of Marketing for Mallinckrodt Medical's Oncology Group, Senior Product Director in their Nuclear Medicine division, and served as a Western Regional Sales Manager for Monsanto Company. Mr. McBeath received his M.B.A. degree with honors from the Olin School of Business at Washington University in St. Louis and his B.S. degree in Biochemistry from the University of Missouri where he was a Curator's Scholar.
back to top